ReviewPharmaceutics2020
Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Emerging Nano Bioinks in Bioprinting: Functional Materials, Engineering Strategies, and Biomedical Applications.Materials (Basel, Switzerland) · 2026Review
- From mesenchymal stem cells to their extracellular vesicles: Progress and prospects for asthma therapy.Asian journal of pharmaceutical sciences · 2024Review
- The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS.Respiratory research · 2024Article
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease.International journal of molecular sciences · 2023Article
- Inhaled Exosomes Genetically Manipulated to Overexpress CD24 (EXO-CD24) as a Compassionate Use in Severe ARDS Patients.Biomedicines · 2023Article
- Regenerative medicine in lung diseases: A systematic review.Frontiers in veterinary science · 2023Review
- Imaging drug delivery to the lungs: Methods and applications in oncology.Advanced drug delivery reviews · 2023Review
- Advancing mesenchymal stem cell therapy for asthma towards clinical translation.Annals of translational medicine · 2022Article
- Clinical perspectives for repairing rotator cuff injuries with multi-tissue regenerative approaches.Journal of orthopaedic translation · 2022Review
- Effect of the area of a lithium niobate transducer on the efficiency of ultrasonic atomization driven by resonance vibration.Ultrasonics sonochemistry · 2022Article
- Cellular Therapy for the Treatment of Paediatric Respiratory Disease.International journal of molecular sciences · 2021Review
- Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases-Intravenous Administration versus Inhalation.Pharmaceutics · 2021Review
- State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced Therapeutic Medicinal Products (ATMP) are a heterogenous group of investigational medicinal products at the forefront of innovative therapies with direct applicability in respiratory diseases. ATMPs include, but are not limited to, stem cells, their secretome, or extracellular vesicles, and each have shown some potential when delivered topically within the lung. This review focuses on that subset of ATMPs. One key mode of delivery that has enabling potential in ATMP validation is aerosol-mediated delivery. The selection of the most appropriate aerosol generator technology is influenced by several key factors, including formulation, patient type, patient intervention, and healthcare economics. The aerosol-mediated delivery of ATMPs has shown promise for the treatment of both chronic and acute respiratory disease in pre-clinical and clinical trials; however, in order for these ATMP device combinations to translate from the bench through to commercialization, they must meet the requirements set out by the various global regulatory bodies. In this review, we detail the potential for ATMP utility in the lungs and propose the nebulization of ATMPs as a viable route of administration in certain circumstances. Further, we provide insight to the current regulatory guidance for nascent ATMP device combination product development within the EU and US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.